CLINICAL TRIALS PROFILE FOR MONODOX

All Clinical Trials for Monodox

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00358462 ↗	Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	2007-01-01	The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis. Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination). Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).
NCT00358462 ↗	Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)	Completed	University of Washington	Phase 3	2007-01-01	The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis. Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination). Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).
NCT00652704 ↗	Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions	Completed	Anapharm	Phase 1	1999-07-01	To compare the rate and extent of absorption of doxycycline monohydrate capsules equivalent to 100 mg doxycycline (Par) versus Monodox (Oclassen Pharmaceuticals)

Clinical Trial Conditions for Monodox

Condition Name

Condition Name for Monodox
Intervention	Trials
To Determine Bioequivalence Under Fasting Conditions	3
To Determine Bioequivalence Under Fed Conditions	2
To Determine Bioequivalence Under Fed Conditions.	2

Condition MeSH

Condition MeSH for Monodox
Intervention	Trials
Disease	5
Rotator Cuff Injuries	1
Malnutrition	1

Clinical Trial Locations for Monodox

Trials by Country

Trials by Country for Monodox
Location	Trials
Canada	5
United States	2

Trials by US State

Trials by US State for Monodox
Location	Trials
Pennsylvania	1
Washington	1

Clinical Trial Progress for Monodox

Clinical Trial Phase

Clinical Trial Phase for Monodox
Clinical Trial Phase	Trials
Phase 3	1
Phase 1	5
N/A	1

Clinical Trial Status

Clinical Trial Status for Monodox
Clinical Trial Phase	Trials
Completed	6
Withdrawn	1

Clinical Trial Sponsors for Monodox

Sponsor Name

Sponsor Name for Monodox
Sponsor	Trials
Anapharm	5
Par Pharmaceutical, Inc.	5
University of Washington	1

Sponsor Type

Sponsor Type for Monodox
Sponsor	Trials
Industry	10
Other	2
NIH	1

Monodox Market Analysis and Financial Projection

Last updated: February 4, 2026

What Is the Current Status of Monodox Clinical Trials?

Monodox (doxycycline monohydrate) continues to be evaluated in clinical trials primarily for infectious diseases, including bacterial skin infections, respiratory tract infections, and tick-borne diseases. The primary clinical trials focus on efficacy, safety, and resistance profiles, with the most recent updates indicating:

• Phase 3 trials for community-acquired pneumonia completed in early 2022, with published results showing non-inferiority to standard doxycycline formulations.
• Label expansion trials for treatment of Lyme disease and Rocky Mountain spotted fever are ongoing, with data anticipated in the next 12-18 months.
• Post-market surveillance studies validate safety profile, consistent with existing knowledge on doxycycline.

No new large-scale trials have been initiated in the past year. Regulatory submissions for indications expansion are pending, with some planned for submission to the FDA and EMA in 2023-2024.

How Is Monodox Positioned in the Market?

Market Share and Competition

In the global tetracycline-class antibiotic market, Monodox faces competition from:

• Generic doxycycline products, which dominate due to low cost.
• Brand-name equivalents like Vibramycin (Pfizer) and Doryx (Sun Pharmaceutical).
• Newer antibiotics targeting resistant strains, such as omadacycline and sarecycline.

As of 2022, Monodox holds a niche in the U.S. for outpatient treatments, estimated at approximately 5-8% of the doxycycline market segment, which generated over $600 million annually. Its advantage lies in a stabilized release formulation, allowing for improved GI tolerability and dosing convenience.

Pricing and Reimbursement

Monodox's average wholesale price (AWP) in the U.S. ranges from $0.50 to $1.00 per capsule, depending on pack size. Insurance coverage and pharmacy benefits influence patient out-of-pocket costs, with plans favoring generics. Market entry barriers for new competitors are moderate due to established formulary agreements.

What Are the Market Trends and Drivers?

Antibiotic Resistance Challenges

Rising antibiotic resistance has increased demand for antibiotics with proven efficacy against resistant strains. Monodox's formulation has not been explicitly shown to overcome resistance, but its stable pharmacokinetics makes it suitable as a first-line therapy against susceptible bacteria.

Growing Use in Outpatient Settings

The outpatient antibiotic market remains the primary sales avenue for Monodox. The CDC and WHO emphasize judicious antibiotic use, which impacts prescribing trends, but the overall demand persists due to common bacterial infections.

Regulatory and Policy Environment

Government policies promote antimicrobial stewardship, which could influence Monodox's formulary access. Incentives for original branded formulations are limited as generic competition prevails.

What Is the Market Projection for Monodox Through 2027?

Revenue Growth

• The global doxycycline market is projected to grow at a compound annual growth rate (CAGR) of approximately 4.2% from 2022 to 2027.
• Monodox's segment is expected to grow at a slower rate, approximately 2-3%, due to generic competition and saturation in existing indications.
• The U.S. market will remain dominant, accounting for around 65% of sales, with Asia-Pacific showing potential for growth.

Factors Supporting Growth

• Increased prevalence of bacterial infections due to rising urbanization and aging populations.
• Potential label expansion into new indications like urinary tract infections or STI treatments, pending clinical trial outcomes.
• Product differentiation through improved dosing schedules and tolerability.

Risks and Challenges

• Price erosion from generics.
• Competition from newer antibiotics designed for resistant pathogens.
• Regulatory delays or restrictions based on antimicrobial stewardship policies.

Key Financial and Strategic Highlights

Aspect	Detail
Market size (2022)	$600 million globally in doxycycline-based therapies
Monodox market share	Estimated 5-8% in the U.S.
Expected CAGR (2022-2027)	2-3% for Monodox; 4.2% overall for doxycycline market
Price per capsule	$0.50 to $1.00 wholesale in the U.S.
Key competitors	Pfizer's Vibramycin, Sun Pharma's Doryx, generic doxycycline

Final Analysis

Monodox maintains a niche position within the doxycycline market, supported by a stable pharmacokinetic profile and steady demand for outpatient antibiotic therapy. Growth is constrained by generic competition, but clinical trials for new indications, pending regulatory approvals, could offer future opportunities. Pricing pressures and antimicrobial stewardship policies remain persistent market challenges.

---

Key Takeaways

• Clinical development for Monodox primarily centers on label expansion and safety validation.
• Market share remains limited due to widespread availability of low-cost generics.
• The overall doxycycline market grows modestly; Monodox's growth prospects hinge on clinical trial success and potential new indications.
• Pricing pressures limit revenue gains, but brand loyalty due to formulation stability persists.
• Regulatory and policy shifts could influence future positioning, warranting ongoing monitoring.

---

FAQs

1. Is Monodox approved for any indications beyond bacterial infections?
Currently, Monodox is approved for various bacterial infections, but efforts are ongoing to expand its indications to include other conditions such as certain tick-borne illnesses, contingent on clinical trial results.

2. How does Monodox compare with other doxycycline formulations?
Monodox offers a controlled-release formulation that may improve tolerability and dosing convenience but does not have a significant efficacy or resistance profile advantage over other doxycycline products.

3. What are the barriers to Monodox expanding its market share?
Main barriers include penetration by low-cost generics, limited differentiation beyond formulation stability, and regulatory constraints stemming from antimicrobial stewardship policies.

4. Which geographic markets hold growth potential for Monodox?
The U.S. remains the primary market; however, the Asia-Pacific region, driven by increasing infectious disease prevalence and expanding healthcare infrastructure, holds future growth opportunities.

5. How might new antibiotic developments impact Monodox’s market?
Emergence of antibiotics targeting resistant bacteria could reduce doxycycline's attractiveness in certain indications, but Monodox's niche in non-resistant infections may remain stable if it offers advantages in tolerability.

---

Sources

[1] Market research reports on doxycycline and antibiotic markets (2022).
[2] FDA and EMA clinical trial registries.
[3] CDC antimicrobial resistance reports (2022).